AU649473B2 - Enterovirus peptides - Google Patents

Enterovirus peptides

Info

Publication number: AU649473B2
Authority: AU; Australia
Prior art keywords: thr; val; ala; gly; amino acid
Prior art date: 1990-08-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU84002/91A

Other languages

English (en)

Other versions

AU8400291A (en

Inventor

Jonas Blomberg

Rudiger Pipkorn

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Replico Medical AB

Original Assignee

Replico Medical AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-16

Filing date

1991-08-16

Publication date

1994-05-26

1991-08-16 Application filed by Replico Medical AB filed Critical Replico Medical AB

1992-03-17 Publication of AU8400291A publication Critical patent/AU8400291A/en

1994-05-26 Application granted granted Critical

1994-05-26 Publication of AU649473B2 publication Critical patent/AU649473B2/en

2011-08-16 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 64
102000004196 processed proteins & peptides Human genes 0.000 title claims description 42
241000709661 Enterovirus Species 0.000 title claims description 13
239000000427 antigen Substances 0.000 claims description 49
102000036639 antigens Human genes 0.000 claims description 49
108091007433 antigens Proteins 0.000 claims description 49
241000709664 Picornaviridae Species 0.000 claims description 37
241000710831 Flavivirus Species 0.000 claims description 36
241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 31
201000010099 disease Diseases 0.000 claims description 31
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
238000003745 diagnosis Methods 0.000 claims description 27
210000002966 serum Anatomy 0.000 claims description 24
238000003018 immunoassay Methods 0.000 claims description 19
125000003275 alpha amino acid group Chemical group 0.000 claims description 16
125000000539 amino acid group Chemical group 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 16
229960005486 vaccine Drugs 0.000 claims description 14
208000015181 infectious disease Diseases 0.000 claims description 12
230000001154 acute effect Effects 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
239000011347 resin Substances 0.000 claims description 8
229920005989 resin Polymers 0.000 claims description 8
238000003556 assay Methods 0.000 claims description 7
230000000405 serological effect Effects 0.000 claims description 7
238000012360 testing method Methods 0.000 claims description 7
208000005155 Picornaviridae Infections Diseases 0.000 claims description 6
230000000890 antigenic effect Effects 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 6
241000991587 Enterovirus C Species 0.000 claims description 5
206010054261 Flavivirus infection Diseases 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 5
238000003127 radioimmunoassay Methods 0.000 claims description 4
241000709687 Coxsackievirus Species 0.000 claims description 3
241000725619 Dengue virus Species 0.000 claims description 3
102000004190 Enzymes Human genes 0.000 claims description 3
108090000790 Enzymes Proteins 0.000 claims description 3
238000003119 immunoblot Methods 0.000 claims description 3
238000012216 screening Methods 0.000 claims description 3
241000710842 Japanese encephalitis virus Species 0.000 claims description 2
241000710772 Yellow fever virus Species 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000003053 immunization Effects 0.000 claims description 2
238000002372 labelling Methods 0.000 claims description 2
239000002184 metal Substances 0.000 claims description 2
-1 microplate Polymers 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
229940051021 yellow-fever virus Drugs 0.000 claims description 2
238000001514 detection method Methods 0.000 claims 1
239000011159 matrix material Substances 0.000 claims 1
LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims 1
102100029905 DNA polymerase epsilon subunit 3 Human genes 0.000 description 27
101710104359 F protein Proteins 0.000 description 27
150000001413 amino acids Chemical class 0.000 description 13
230000009257 reactivity Effects 0.000 description 9
101710197658 Capsid protein VP1 Proteins 0.000 description 8
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
241000700605 Viruses Species 0.000 description 8
101710132601 Capsid protein Proteins 0.000 description 7
101710118046 RNA-directed RNA polymerase Proteins 0.000 description 7
101710108545 Viral protein 1 Proteins 0.000 description 7
238000000034 method Methods 0.000 description 6
230000003612 virological effect Effects 0.000 description 5
208000006740 Aseptic Meningitis Diseases 0.000 description 4
206010027201 Meningitis aseptic Diseases 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
206010014909 Enterovirus infection Diseases 0.000 description 3
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 3
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
241001144416 Picornavirales Species 0.000 description 3
230000008859 change Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
241001466953 Echovirus Species 0.000 description 2
101710091045 Envelope protein Proteins 0.000 description 2
108700010908 HIV-1 proteins Proteins 0.000 description 2
241000709721 Hepatovirus A Species 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
208000000474 Poliomyelitis Diseases 0.000 description 2
101710188315 Protein X Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
102100021696 Syncytin-1 Human genes 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
206010014599 encephalitis Diseases 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000011835 investigation Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
241000238876 Acari Species 0.000 description 1
108091032955 Bacterial small RNA Proteins 0.000 description 1
235000011297 Brassica napobrassica Nutrition 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000709677 Coxsackievirus B1 Species 0.000 description 1
241000256113 Culicidae Species 0.000 description 1
208000001490 Dengue Diseases 0.000 description 1
206010012310 Dengue fever Diseases 0.000 description 1
241000710829 Dengue virus group Species 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
206010057199 Flaviviral infections Diseases 0.000 description 1
208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
241000710198 Foot-and-mouth disease virus Species 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
206010061308 Neonatal infection Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000003152 Yellow Fever Diseases 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
208000025729 dengue disease Diseases 0.000 description 1
238000012850 discrimination method Methods 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
208000012022 enterovirus infectious disease Diseases 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000499 gel Substances 0.000 description 1
108010023958 glycyl-threonyl-alanyl-methionyl-arginyl-isoleucyl-leucyl-glycyl-glycyl-valyl-isoleucine Proteins 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000012070 reactive reagent Substances 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
238000011282 treatment Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)

AU84002/91A 1990-08-16 1991-08-16 Enterovirus peptides Ceased AU649473B2 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE9002671		1990-08-16
SE9002671A SE470074B (sv)	1990-08-16	1990-08-16	Förfarande för diagnos av picorna- och/eller flavivirusinfektion, peptider, diagnostiska antigener och vaccinkomposition med dessa peptider
PCT/SE1991/000542 WO1992003475A1 (en)	1990-08-16	1991-08-16	Enterovirus peptides

Publications (2)

Publication Number	Publication Date
AU8400291A AU8400291A (en)	1992-03-17
AU649473B2 true AU649473B2 (en)	1994-05-26

Family

ID=20380170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU84002/91A Ceased AU649473B2 (en)	1990-08-16	1991-08-16	Enterovirus peptides

Country Status (4)

Country	Link
EP (1)	EP0546031A1 (de)
AU (1)	AU649473B2 (de)
SE (1)	SE470074B (de)
WO (1)	WO1992003475A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE384795T1 (de)	1998-12-31	2008-02-15	Novartis Vaccines & Diagnostic	Modifizierte hiv env polypeptide
AU2002320314A1 (en)	2001-07-05	2003-01-21	Chiron, Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en)	2001-08-31	2003-09-11	Megede Jan Zur	Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
BE1022174B1 (fr) *	2013-03-15	2016-02-24	Glaxosmithkline Biologicals S.A.	Vaccin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT384363B (de) *	1982-10-05	1987-11-10	Immuno Ag	Verfahren zur verwendung von antigenreaktiven peptiden zur herstellung von gegen fsme-virusinfektionen wirksamen vakzinen
DE3650175T3 (de) *	1985-04-29	2007-09-06	Bio-Rad Laboratories, Inc., Hercules	Synthetische antigene zum nachweis von aids.
JPH0768267B2 (ja) *	1986-06-05	1995-07-26	財団法人阪大微生物病研究会	フラビウイルス抗原
WO1988003032A1 (en) *	1986-10-27	1988-05-05	Fournier Maurielle J	Diagnosis of and vaccine for japanese encephalitis virus and related viruses
EP0284791B1 (de) *	1987-03-20	1995-05-03	IMMUNO Aktiengesellschaft	DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung
JPH084508B2 (ja) *	1987-09-16	1996-01-24	国立予防衛生研究所長	組み換えワクチニアウイルス
GB8821077D0 (en) *	1988-09-08	1988-10-05	Wellcome Found	Peptides

1990
- 1990-08-16 SE SE9002671A patent/SE470074B/sv not_active IP Right Cessation
1991
- 1991-08-16 WO PCT/SE1991/000542 patent/WO1992003475A1/en not_active Application Discontinuation
- 1991-08-16 EP EP91915656A patent/EP0546031A1/de not_active Withdrawn
- 1991-08-16 AU AU84002/91A patent/AU649473B2/en not_active Ceased

Also Published As

Publication number	Publication date
SE9002671D0 (sv)	1990-08-16
WO1992003475A1 (en)	1992-03-05
EP0546031A1 (de)	1993-06-16
AU8400291A (en)	1992-03-17
SE470074B (sv)	1993-11-01
SE9002671L (sv)	1992-02-17

Publication	Publication Date	Title
KR930008092B1 (ko)	1993-08-25	Hcv에 대한 항체의 검출, hcv 감염의 진단, 및 백신으로서의 그 예방에 특이적인 합성펩티드
KR940000755B1 (ko)	1994-01-29	Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
JP3514680B2 (ja)	2004-03-31	Ｃ型肝炎ウイルス（ｈｃｖ）ポリペプチド
JP3156200B2 (ja)	2001-04-16	新規のｈｃｖ分離株
Chiba et al.	2000	Sapporo virus: history and recent findings
CN1360678B (zh)	2013-07-03	借助ns1糖蛋白对黄病毒进行早期检测的方法及其应用
Zhao et al.	2015	A comprehensive study of neutralizing antigenic sites on the hepatitis E virus (HEV) capsid by constructing, clustering, and characterizing a tool box
JPH04253998A (ja)	1992-09-09	Ｃ型肝炎アッセイ
Cello et al.	1993	Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides
JPH07501442A (ja)	1995-02-16	Ｃ型肝炎ウイルス検査
CN113607952B (zh)	2022-03-11	非洲猪瘟病毒阻断elisa抗体检测试剂盒及其制备方法和应用
Lennette et al.	1988	Picornaviridae: the enteroviruses (polioviruses, coxsackieviruses, echoviruses)
Favorov et al.	1994	Enzyme immunoassay for the detection of antibody to hepatitis E virus based on synthetic peptides
CN105418738A (zh)	2016-03-23	***病毒a型抗原多肽、融合抗原多肽及疫苗
Melnick	1997	Poliovirus and other enteroviruses
EP0828756A2 (de)	1998-03-18	Diagnose von, und impfung gegen, ein minussträngiges rns-virus, durch die verwendung eines isolierten unbehandelten polypeptid
JPH06510861A (ja)	1994-12-01	Ｃ型肝炎アッセイ
Yeung et al.	1989	The cell attachment proteins of type 1 and type 3 reovirus are differentially susceptible to trypsin and chymotrypsin
US5824506A (en)	1998-10-20	Dengue virus peptides and methods
AU649473B2 (en)	1994-05-26	Enterovirus peptides
EP0747394A2 (de)	1996-12-11	Synthetische Peptide des Hepatitis GB Virus und ihre Verwendung
Kurstak et al.	1986	Enzyme immunoassays and related procedures in diagnostic medical virology
Qi et al.	1995	Synthesis and application of hepatitis E virus peptides to diagnosis
RU2811996C1 (ru)	2024-01-22	Тест-система для определения титра антител против 146S частиц вируса ящура генотипа SAT-2/IV с помощью жидкофазного ИФА
US20050214748A1 (en)	2005-09-29	Peptide-based diagnostic reagents for SARS